Literature DB >> 24567379

Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans.

Weijing Cai1, Jaime Uribarri, Li Zhu, Xue Chen, Shobha Swamy, Zhengshan Zhao, Fabrizio Grosjean, Calogera Simonaro, George A Kuchel, Michal Schnaider-Beeri, Mark Woodward, Gary E Striker, Helen Vlassara.   

Abstract

Age-associated dementia and Alzheimer's disease (AD) are currently epidemic. Neither their cause nor connection to the metabolic syndrome (MS) is clear. Suppression of deacetylase survival factor sirtuin 1 (SIRT1), a key host defense, is a central feature of AD. Age-related MS and diabetes are also causally associated with suppressed SIRT1 partly due to oxidant glycotoxins [advanced glycation end products (AGEs)]. Changes in the modern diet include excessive nutrient-bound AGEs, such as neurotoxic methyl-glyoxal derivatives (MG). To determine whether dietary AGEs promote AD, we evaluated WT mice pair-fed three diets throughout life: low-AGE (MG(-)), MG-supplemented low-AGE (MG(+)), and regular (Reg) chow. Older MG(+)-fed mice, similar to old Reg controls, developed MS, increased brain amyloid-β42, deposits of AGEs, gliosis, and cognitive deficits, accompanied by suppressed SIRT1, nicotinamide phosphoribosyltransferase, AGE receptor 1, and PPARγ. These changes were not due to aging or caloric intake, as neither these changes nor the MS were present in age-matched, pair-fed MG(-) mice. The mouse data were enhanced by significant temporal correlations between high circulating AGEs and impaired cognition, as well as insulin sensitivity in older humans, in whom dietary and serum MG levels strongly and inversely associated with SIRT1 gene expression. The data identify a specific AGE (MG) as a modifiable risk factor for AD and MS, possibly acting via suppressed SIRT1 and other host defenses, to promote chronic oxidant stress and inflammation. Because SIRT1 deficiency in humans is both preventable and reversible by AGE reduction, a therapeutic strategy that includes AGE reduction may offer a new strategy to combat the epidemics of AD and MS.

Entities:  

Keywords:  caloric restriction; insulin resistance; neural; nutrition; obesity

Mesh:

Substances:

Year:  2014        PMID: 24567379      PMCID: PMC3977256          DOI: 10.1073/pnas.1316013111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment.

Authors:  Naila Ahmed; Usman Ahmed; Paul J Thornalley; Klaus Hager; Gerd Fleischer; Gerald Münch
Journal:  J Neurochem       Date:  2005-01       Impact factor: 5.372

2.  Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy.

Authors:  T Koschinsky; C J He; T Mitsuhashi; R Bucala; C Liu; C Buenting; K Heitmann; H Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

3.  The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions.

Authors:  M X Fu; J R Requena; A J Jenkins; T J Lyons; J W Baynes; S R Thorpe
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

4.  Glycation and microglial reaction in lesions of Alzheimer's disease.

Authors:  D W Dickson; S Sinicropi; S H Yen; L W Ko; L A Mattiace; R Bucala; H Vlassara
Journal:  Neurobiol Aging       Date:  1996 Sep-Oct       Impact factor: 4.673

5.  Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis.

Authors:  J J Li; D Dickson; P R Hof; H Vlassara
Journal:  Mol Med       Date:  1998-01       Impact factor: 6.354

6.  Advanced glycation end products contribute to amyloidosis in Alzheimer disease.

Authors:  M P Vitek; K Bhattacharya; J M Glendening; E Stopa; H Vlassara; R Bucala; K Manogue; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

7.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.

Authors:  R Bucala; Z Makita; G Vega; S Grundy; T Koschinsky; A Cerami; H Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

8.  Increased risk of type 2 diabetes in Alzheimer disease.

Authors:  Juliette Janson; Thomas Laedtke; Joseph E Parisi; Peter O'Brien; Ronald C Petersen; Peter C Butler
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

9.  Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine.

Authors:  G A Zimmerman; M Meistrell; O Bloom; K M Cockroft; M Bianchi; D Risucci; J Broome; P Farmer; A Cerami; H Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

10.  Suppression of native defense mechanisms, SIRT1 and PPARγ, by dietary glycoxidants precedes disease in adult humans; relevance to lifestyle-engendered chronic diseases.

Authors:  Jaime Uribarri; Weijing Cai; Renata Pyzik; Susan Goodman; Xue Chen; Li Zhu; Maya Ramdas; Gary E Striker; Helen Vlassara
Journal:  Amino Acids       Date:  2013-05-01       Impact factor: 3.520

View more
  52 in total

Review 1.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

Review 2.  Cellular Metabolism and Aging.

Authors:  Andre Catic
Journal:  Prog Mol Biol Transl Sci       Date:  2018-02-01       Impact factor: 3.622

Review 3.  Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.

Authors:  Remi Neviere; Yichi Yu; Lei Wang; Frederic Tessier; Eric Boulanger
Journal:  Glycoconj J       Date:  2016-06-08       Impact factor: 2.916

Review 4.  Dietary advanced glycation end products and their role in health and disease.

Authors:  Jaime Uribarri; María Dolores del Castillo; María Pía de la Maza; Rosana Filip; Alejandro Gugliucci; Claudia Luevano-Contreras; Maciste H Macías-Cervantes; Deborah H Markowicz Bastos; Alejandra Medrano; Teresita Menini; Manuel Portero-Otin; Armando Rojas; Geni Rodrigues Sampaio; Kazimierz Wrobel; Katarzyna Wrobel; Ma Eugenia Garay-Sevilla
Journal:  Adv Nutr       Date:  2015-07-15       Impact factor: 8.701

5.  Advanced glycation end products, dementia, and diabetes.

Authors:  Simon Lovestone; Ulf Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-25       Impact factor: 11.205

Review 6.  Gut Microbiota Disorder, Gut Epithelial and Blood-Brain Barrier Dysfunctions in Etiopathogenesis of Dementia: Molecular Mechanisms and Signaling Pathways.

Authors:  Menizibeya O Welcome
Journal:  Neuromolecular Med       Date:  2019-05-21       Impact factor: 3.843

Review 7.  Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease.

Authors:  Subbiah Pugazhenthi; Limei Qin; P Hemachandra Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-05-06       Impact factor: 5.187

Review 8.  Cellular mechanisms and consequences of glycation in atherosclerosis and obesity.

Authors:  Raquel López-Díez; Alexander Shekhtman; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Biochim Biophys Acta       Date:  2016-05-08

Review 9.  Dietary glycemia as a determinant of health and longevity.

Authors:  Elizabeth A Whitcomb; Chung-Jung Chiu; Allen Taylor
Journal:  Mol Aspects Med       Date:  2015-08-14

10.  Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial.

Authors:  Helen Vlassara; Weijing Cai; Elizabeth Tripp; Renata Pyzik; Kalle Yee; Laurie Goldberg; Laurie Tansman; Xue Chen; Venkatesh Mani; Zahi A Fayad; Girish N Nadkarni; Gary E Striker; John C He; Jaime Uribarri
Journal:  Diabetologia       Date:  2016-07-29       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.